Caveolin-1 enhances brain metastasis of non-small cell lung cancer, potentially in association with the epithelial-mesenchymal transition marker SNAIL

Yeong-Jin Kim1†, Ju-Hwi Kim1†, Ok Kim2, Eun-Jung Ahn1, Se-Jeong Oh1,2, Md Rashedunnabi Akanda2,7, In-Jae Oh3, Shin Jung1, Kyung-Keun Kim4, Jae-Hyuk Lee6, Hyung-Seok Kim5, Hangun Kim6, Kyung-Hwa Lee2* and Kyung-Sub Moon1*

Abstract
Background: Caveolin-1 (Cav-1) plays an important role in the development of various human cancers. We investigated the relationship between Cav-1 expression and non-small cell lung cancer (NSCLC) progression in the context of brain metastasis (BM).

Methods: Cav-1 expression was investigated in a series of 102 BM samples and 49 paired primary NSCLC samples, as well as 162 unpaired primary NSCLC samples with (63 cases) or without (99 cases) metastasis to distant organs. Human lung cancer cell lines were used for in vitro functional analysis.

Results: High Cav-1 expression in tumor cells was observed in 52% (38/73) of squamous cell carcinomas (SQCs) and 33% (45/138) of non-SQCs. In SQC, high Cav-1 expression was increased after BM in both paired and unpaired samples of lung primary tumors and BM (53% vs. 84% in paired samples, \( P = 0.034 \); 52% vs. 78% in unpaired samples, \( P = 0.020 \)). Although the difference in median overall survival in patients NSCLC was not statistically significant, high Cav-1 expression in tumor cells (\( P = 0.005 \), hazard ratio 1.715, 95% confidence index 1.175–2.502) was independent prognostic factors of overall survival on multivariate Cox regression analyses, in addition to the presence of BM and non-SQC type. In vitro assays revealed that Cav-1 knockdown inhibited the invasion and migration of lung cancer cells. Genetic modulation of Cav-1 was consistently associated with SNAIL up- and down-regulation. These findings were supported by increased SNAIL and Cav-1 expression in BM samples of SQC.

Conclusions: Cav-1 plays an important role in the BM of NSCLC, especially in SQC. The mechanism may be linked to SNAIL regulation.

Keywords: Brain metastasis, Caveolin-1, Epithelial-mesenchymal transition, Non-small cell lung cancer, SNAIL

*Correspondence: mdkaylee@chonnam.ac.kr; moonks@chonnam.ac.kr
†Yeong-Jin Kim and Ju-Hwi Kim equally contributed to this article
1 Department of Neurosurgery, Chonnam National University Research Institute of Medical Science, Chonnam National University Hwasun Hospital and Medical School, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128, South Korea
2 Department of Pathology, Chonnam National University Research Institute of Medical Science, Chonnam National University Hwasun Hospital and Medical School, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128, South Korea
Full list of author information is available at the end of the article

© The Authors 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Lung cancer remains the 2nd common human cancer and the leading cause of cancer-associated death in the United States. The 5-year overall survival (OS) rate is only 19%, despite advanced treatment modalities [1]. Lung cancers are classified into several types based on the histologic classification. Non-small cell lung cancer (NSCLC), represented by adenocarcinoma (ADC) and squamous cell carcinoma (SQC), presents distinguished clinical courses with differences in treatment planning and prognosis prediction, compared to small cell lung cancer (SCLC) [2]. With the incidence of histologic subtype, ADC is the most common type, followed by SQC, and SCLC [3]. Brain metastasis (BM) develops in approximately 40% of patients with NSCLC and generally results in a dismal prognosis [4–6]. Effective therapy to manage the progressive biology of this disease continues to be debated. Therefore, a deeper understanding of the molecular pathogenesis underlying BM of NSCLC is essential for improving patient prognosis.

Caveolae, omega-shaped vesicular invaginations of the plasma membrane, consist of three major structural proteins: caveolin (Cav)-1, -2, and -3. Among them, Cav-1 is the substantial structural protein of caveolae. Caveolae are believed to function as vesicular transporters, cholesterol homeostasis modulators, and a signal platform where Cav-1 interacts with signaling molecules and regulates cell proliferation, differentiation, transformation, and metastasis [7–10]. An increasing number of studies have evaluated Cav-1 expression in cancer. Several studies have reported that Cav-1 plays a tumor-suppressive role, while others have revealed that increased expression of Cav-1 is implicated in tumor progression and metastasis [11–24].

Cav-1 functions as a tumor suppressor in SCLC and is inversely required for tumor cell survival and growth in NSCLC [25]. Cav-1 expression in pleomorphic carcinoma of the lung is correlated with a poor prognosis [26]. With the different expression of Cav-1 based on the histopathology, however, there are some debates in the clinical implication of Cav-1 in NSCLC patients [27–37]. Cav-1 exhibits increased expression during metastasis via interference with cell adhesion molecules, causing a loss of polarity during migration [38, 39]. Previous studies have reported that up-regulation of Cav-1 is related to epithelial-mesenchymal transition (EMT) and influences cancer cell motility [40, 41]. Reversely, EMT is associated with Cav-1 expression in human cancer [16, 42].

To date, few studies have reported that BM is correlated with Cav-1 expression in lung cancer [36, 37]. In the present study, Cav-1 expression was evaluated in relation to lung cancer histotypes, the presence of BM, and prognosis. Furthermore, a possible relationship with Cav-1 expression and EMT markers was investigated in NSCLC cell lines, along with changes in their migration and invasion abilities.

Methods
Human tissue specimens and clinical data
From January 1, 2007 to December 31, 2012, 105 cases affected by BM originating from NSCLC were enrolled (tissue specimens from the metastatic brain tumors of 102 patients were obtained by surgical resection; the remaining 3 patients were treated with Gamma knife radiosurgery for BM). A total of 211 NSCLC patients with primary cancer resected at the Lung and Esophageal Cancer Clinic were enrolled in this study. The patients were classified into four groups (Fig. 1a and Table 1). Group 1 comprised BM cases originating from NSCLC, Group 2 comprised primary NSCLC cases paired to the Group 1 cases, Group 3 comprised primary NSCLC cases without any systemic metastasis, and Group 4 comprised primary NSCLC cases with distant metastasis to organs other than the brain. Patients with preoperative radiotherapy or chemotherapy were excluded. Clinical information was retrospectively collected from clinical and pathological records. Pathological diagnosis was confirmed based on World Health Organization classifications. BM was confirmed by gadolinium-enhanced magnetic resonance imaging. OS was calculated as the time from the date of diagnosis to the date of death or the last follow-up visit.

This study was approved by the Institutional Review Board of Chonnam National University Hwasun Hospital (CNUHH-2016-086). Written informed consent to use clinical data and pathological samples was obtained from patients or their legal surrogates.

Immunohistochemistry (IHC)
All immunostained slides were evaluated twice by experienced pathologists (LJH and LKH) blinded to the clinical details. IHC was performed as described previously [43]. Tissue sections were immunostained with specific antibodies against Cav-1 (1:800, BD Biosciences, Franklin Lakes, NJ, USA) and SNAIL (1:100, Santa Cruz Biotechnology Inc., Dallas, TX, USA) using a Bond-Max auto-stainer system (Leica Microsystems, Buffalo Grove, IL, USA). Negative controls were processed in the absence of primary antibodies. The Cav-1 antibody stained the cytoplasmic borders and cytoplasm of cancer cells. The SNAIL antibody mainly stained the cytoplasm of cancer cells, along with changes in their migration and invasion abilities.
expression). These samples were also grouped according to staining intensity as described above (Fig. 1b).

Cell culture and transfection
Human lung cancer cell lines (H1299, H157, H358, H520, H2170, and H1650) were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; WELGENE, Gyeongsan, South Korea) supplemented with 10% fetal bovine serum (FBS; WELGENE) in a humidified atmosphere of 5% CO2 at 37 °C. Cav-1-specific small interfering RNA (siRNA) (BIONEER, Daejeon, South Korea) was transfected into lung cancer cells using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Control siRNA (BIONEER) was used as a negative control. Cav-1 knockdown was confirmed at the mRNA and protein levels. SNAIL-specific siRNA (BIONEER) was transfected into Cav-1-overexpressing H157 cells, as above mentioned. Knockdown and overexpression of Cav-1 were conducted as described previously [44]. Recombinant lentivirus was purchased from Macrogen LentiVector Institute (Seoul, South Korea). pLKO.1 (Sigma–Aldrich, St. Louis, MO, USA) was used for small hairpin RNA (shRNA) knockdown of Cav-1, and pWPI (Addgene, Cambridge, MA, USA) was used for overexpression of Cav-1. Supernatant with viral particles was obtained 48 h after incubation, passed through a 0.45-mm membrane filter (Nalgene, Rochester, NY, USA), and stored at −70 °C until use. Transfection efficiency was assessed by fluorescence imaging and immunoblotting. A non-specific plasmid encoding β-galactosidase was used as a control in each transfection.

Reverse transcriptase polymerase chain reaction (RT-PCR) and quantitative RT-PCR (qRT-PCR)
RT-PCR and qRT-PCR were performed as described previously [43]. The following primers were used: GAPDH

| Table 1 Number of cases used in this study according to sample groups |
|---------------------------------|-------|-------|-------|-------|
| Variables                        | Group 1 | Group 2 | Group 3 | Group 4 |
| Age (mean 62.7 years)            |       |       |       |       |
| < 63                             | 49    | 24    | 34    | 26    |
| ≥ 63                             | 56    | 25    | 65    | 37    |
| Sex                              |       |       |       |       |
| Male                             | 81    | 39    | 76    | 50    |
| Female                           | 24    | 10    | 23    | 13    |
| Histological type                |       |       |       |       |
| SQC                              | 27    | 19    | 29    | 25    |
| ADC                              | 62    | 24    | 56    | 31    |
| LCC                              | 16    | 6     | 14    | 7     |
| Total                            | 105a  | 49b   | 99    | 63    |

Group 1—Cases of BM from NSCLC
Group 2—Primary lung carcinoma cases paired to Group 1 cases
Group 3—Primary lung carcinoma cases without metastasis
Group 4—Primary lung carcinoma cases with distant metastasis to organs other than brain
SQC, squamous cell carcinoma; ADC, adenocarcinoma; LCC, large cell carcinoma
a Composed of 102 cases with open brain surgery and 3 cases with gamma knife radiosurgery (lung primary samples only)
b Not including 3 patients underwent gamma knife radiosurgery
(forward: 5′-AGT TGT CAT GGA TGA CCT TG GCA TTG GCA GCG-3′; reverse: 5′-ATC ACC ATC TTC CAG GAG CGA-3′), SNAIL (forward: 5′-TTC GCC ATT CTC TCT TTT CT-3′; reverse: 5′-CAG CTT CAA AGA GTG GGT CA-3′). Total RNA from cells was prepared using TRIzol reagent (Takara, Mountain View, CA, USA). After estimating the RNA concentration on the NanoDrop ND 1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA), 100 μg RNA were transcribed into cDNA using the LeGene Express 1st Strand cDNA Synthesis System Kit (LeGene Biosciences, San Diego, CA, USA). cDNA was amplified by h-Taq DNA Polymerase (SolGent, Daejeon, South Korea) and target primers. Amplification conditions were as follows: 15 min of denaturation at 95 °C, followed by 35 cycles of denaturation for 30 s at 95 °C, annealing for 30 s at 60 °C, and extension for 30 s at 72 °C, followed by a final extension for 7 min at 72 °C. No more than 35 PCR cycles were performed. Amplification of the endogenous reference gene GAPDH was used as an internal control. PCR products were electrophoresed on an agarose gel containing ethidium bromide and visualized using the Gel Doc EZ imager (Bio-Rad Laboratories, Hercules, CA, USA).

qRT-PCR was conducted using the veriQuest SYBR Green qPCR Kit (Affymetrix Inc., Santa Clara, CA, USA) and CFX96 Touch™ Real-time PCR Detection System (Bio-Rad Laboratories) running CFX manager software (Bio-Rad Laboratories). Amplification conditions were as follows: hot start for 10 min at 95 °C, followed by 40 cycles of denaturation for 15 s at 95 °C, annealing for 30 s at 60 °C, and elongation for 30 s at 72 °C. Gene expression was normalized relative to GAPDH expression in the same sample using the 2−ΔΔCt method. All PCR experiments were repeated at least three times independently, and the average was calculated.

Western blot analysis
The primary and secondary antibodies used in this study are listed in Additional file 1 (Table S1). Proteins were extracted from lysed cells using RIPA buffer (Bio Solution, Seoul, South Korea) supplemented with a protease inhibitor cocktail (Roche, Mannheim, Germany). After centrifugation, proteins (20–40 μg) were separated by 10% polyacrylamide gel electrophoresis containing 0.1% sodium dodecyl sulfate and electrophoretically transferred to polyvinylidene fluoride membranes (GE Healthcare Life Sciences, Marlborough, MA, USA). The membranes were probed with specific primary antibodies overnight, followed by anti-rabbit or anti-mouse immunoglobulin secondary antibodies conjugated to horseradish peroxidase. Bands were detected by an electrochemiluminescence system (Millipore, Burlington, MA, USA) and quantitated on the LAS-4000 luminescent image analyzer (Fujifilm, Tokyo, Japan).

Cell invasion and migration assay
Cell invasion was measured using Transwells with chambers separated by filters with an 8 μm pore size (Corning Inc., Corning, NY, USA). Control or knockdown cells (1 × 10⁵ H157 cells and 1 × 10⁵ H1299 cells in 0.35 ml serum-free DMEM) were loaded into the upper chamber. For rescue assay by SNAIL-specific siRNA, 2 × 10⁴ mock or Cav-1-overexpressing H157 cells were loaded. Subsequently, the lower chamber was filled with 0.6 ml DMEM supplemented with 0.2% (w/v) bovine serum albumin and 5 μg/ml human plasma fibronectin (Calbiochem, San Diego, CA, USA). After incubation for 24 h at 37 °C, cells that had invaded the bottom side of the Transwell were fixed and stained using the Hemacolor Rapid Staining Kit (Merck, Darmstadt, Germany). Cell numbers from three to five random microscopic fields (each 0.5 mm²) were counted under a light microscope.

Gene-modulated H1299 and H157 cells in pairs were seeded into 96-well transparent tissue culture plates (ESSEN Bioscience, Ann Arbor, MI, USA) and cultured to 90% confluence in DMEM supplemented with 10% FBS for 24 h. Using a 96-well wound-maker (ESSEN Bioscience), a straight, uniform scratch was made through adherent cells. After the addition of serum-free DMEM, the plates were placed in IncuCyte™ (ESSEN Bioscience) and scanned at 0, 6, 12, and 24 h. The distance was measured using ZOOM software (ESSEN Bioscience) and normalized to 100%. Each experiment was conducted at least three times independently.

Statistical analysis
All data were analyzed using SPSS version 23.0 software for Windows (Armonk, NY, USA). To analyze the effects of Cav-1 expression on categorical variables, Pearson Chi square test or Wilcoxon signed ranks test was used where appropriate. The effects of individual variables on OS were determined by univariate (Kaplan–Meier method with comparison by log-rank tests) and multivariate (Cox’s proportional hazards model) analyses. We analyzed the in vitro data using GraphPad Prism version 6.07 software for Windows (GraphPad, La Jolla, CA, USA). Data are presented as the mean ± standard error of the mean. The level of significance was set at P < 0.05.

Results
Cav-1 expression is related to BM in NSCLC
A total of 211 tissue samples obtained from primary NSCLC were tabulated by age, sex, histology, metastatic lesion, and Cav-1 expression (Table 2). Regarding
histology, tumor cells of ADC showed lower Cav-1 expression (high Cav-1 expression, 28%), whereas SQC and large cell carcinoma showed relatively higher levels of Cav-1 expression (52% and 59%, respectively). Compared with the SQC and non-SQC groups, the differences in high Cav-1 expression were statistically significant (52% vs. 33%, respectively, \( P = 0.006 \)).

The comparison of Cav-1 expression in 49 paired cases (Group 2: BM and primary lung cancer from the same patient) according to histology (SQC vs. non-SQC) revealed histotype-associated expression results (Table 3). In SQC, Cav-1 expression was significantly different between the primary lung and metastatic brain lesions. Primary lung lesions showed an intermediate level of Cav-1 expression (high Cav-1 expression, 10/19 [53%]), whereas BM showed a high level of Cav-1 expression (16/19, 84%, \( P = 0.034 \)). This difference was due to the shift to high Cav-1 expression with BM development compared with the primary lung lesions. In non-SQC, tumor cells maintained a low level of Cav-1 expression in BM compared with the primary lesion (27% vs. 30%, respectively, \( P = 0.564 \)).

The analysis of Cav-1 expression between all BM (\( N = 102 \)) and primary NSCLC (\( N = 211 \)) cases revealed a similar pattern (Table 4). In SQC, Cav-1 expression was frequently higher in BM than the primary lung lesion (cases with high Cav-1 expression, 78% vs. 52%, respectively, \( P = 0.020 \)). In non-SQC, tumor cells showed low Cav-1 expression in both primary lung cancer and BM (cases with high Cav-1 expression, 33% vs. 27%, respectively, \( P = 0.368 \)).

Collectively, tumor cells in the primary lung lesion showed higher Cav-1 expression in the SQC group than in the non-SQC group. Cav-1 expression in the SQC group was further elevated in tumor cells of BM compared to the primary lung lesions.

Cav-1 expression in the primary lung lesion may relate to survival in NSCLC patients
Clinical features, including age, sex, histology, presence of BM, and Cav-1 expression in the tumor cells, of 211 primary NSCLC patients were analyzed (Table 5 and Fig. 2). Although the median OS was shorter in patients with high Cav-1 expression than in those with low Cav-1 expression in tumor cells, the difference was not statistically significant (71.0 vs. 73.1 months, respectively, \( P = 0.260 \)). Univariate analyses revealed that the presence of BM was significantly prognostic of OS (\( P < 0.001 \)). Moreover, multivariate Cox regression analyses revealed that the presence of BM (\( P < 0.001 \), hazard ratio [HR] 0.181, 95% confidence index [CI] 0.124–0.264), non-SQC type (\( P = 0.007 \), HR 1.762, 95% CI 1.168–2.659), and Cav-1 expression in tumor cells (\( P = 0.005 \), HR 1.715, 95% CI 1.175–2.502) were independent prognostic factors of OS. Interestingly, Cav-1 expression in BM was partly related with OS in NSCLC patients (\( P = 0.116 \), Additional file 2: Figure S1).

Knockdown of Cav-1 decreases cell migration and invasion
To investigate the role of Cav-1 in lung cancer cells, Cav-1 expression was evaluated by Western blotting and RT-PCR in various lung cancer cell lines. Among them, H157 and H1299 cell lines with up-regulated expression of Cav-1 were selected. Knockdown of Cav-1 using
siRNA suppressed endogenous Cav-1 mRNA and protein expression in these cell lines (Fig. 3). Cav-1 knockdown in lung cancer cell lines reduced cell migration in vitro (Fig. 4a). After 24 h, the artificial wound gaps became significantly narrower in plates of mock-transfected than Cav-1 siRNA-transfected H1299 and H157 cells (wound gap distance decrease, 68% and 27%, respectively). Cav-1 knockdown in lung SQC cell lines significantly reduced cell invasion in vitro, i.e., a significantly smaller number of H1299 and H157 cells transiently transfected with Cav-1 siRNA migrated through the membrane compared with mock-transfected cells (cell number decrease, 75% and 73%, respectively) (Fig. 4b).

Knockdown of Cav-1 decreases expression of EMT markers and EMT-regulating genes

To identify factors associated with alterations in cell invasion and migration caused by modulation of Cav-1 expression, the expression levels of EMT markers and EMT-regulating genes were determined in H1299 and H157 cells (Fig. 4c). Transient Cav-1 knockdown in both lung cancer cell lines reduced the expression of EMT markers, including N-cadherin and fibronectin, at the protein and mRNA levels. Among the EMT-regulating genes, SNAIL was consistently down-regulated by Cav-1 knockdown in both cell lines.

Increased Cav-1 expression is accompanied by increased SNAIL expression in SQC

Based on the IHC analysis of Cav-1 expression, Cav-1 expression was higher in BM than in primary lung cancer of the SQC type. In vitro assays revealed that Cav-1 knockdown led to decreased invasion and migration abilities with a reduction in SNAIL expression. To verify the relationship between Cav-1 and SNAIL in tissue samples, we compared SNAIL expression with Cav-1 expression according to histologic type. In the SQC type, the intensity of SNAIL expression increased concordantly with

| Table 4 Comparison of Tumor Cav-1 expression in 102 samples of BM and 211 samples of primary NSCLC according to histology |
|-----------------|-------------|-------------|---|
|                  | No.         | Tumor Cav-1 | P value |        |
|                  |             | Low         | High    | a |
| SQC              |             |             |         |    |
| BM               | 27          | 6 (22%)     | 21 (78%)| 0.020 |
| Lung             | 73          | 35 (48%)    | 38 (52%)|    |
| Sum              | 100         | 41 (41%)    | 59 (59%)|    |
| Non-SQC          |             |             |         |    |
| BM               | 75          | 55 (73%)    | 20 (27%)| 0.368 |
| Lung             | 138         | 93 (67%)    | 45 (33%)|    |
| Sum              | 213         | 148 (70%)   | 65 (30%)|    |
| Total            | 102         | 61 (60%)    | 41 (40%)| 0.884 |
| Lung             | 211         | 128 (61%)   | 86 (39%)|    |
| Sum              | 313         | 189 (60%)   | 127 (40%)|    |
| SQC, squamous cell carcinoma |

* Pearson Chi square test

| Table 5 Univariate and multivariate analysis for overall survival predictors in 211 patients with primary NSCLC |
|-----------------|-------------|-------------|---|
| Characteristics | No.         | Mean survival (months) | P value (univariate) | P-value (multivariate) | Hazard ratio | 95% Confidence index |
| Age             |             |               |                       |                       |             |                        |
| < 63            | 84          | 83.1          | 0.056                 | 0.109                 | 1           | 0.935–1.942 |
| ≥ 63            | 127         | 66.3          | 1.348                 |                       |             |                        |
| Sex             |             |               |                       |                       |             |                        |
| Male            | 165         | 68.7          | 0.099                 | 0.162                 | 1           | 0.456–1.141 |
| Female          | 46          | 90.5          | 0.721                 |                       |             |                        |
| Histology       |             |               |                       |                       |             |                        |
| SQC             | 73          | 78.7          | 0.280                 | 0.007                 | 1           | 1.168–2.659 |
| Non-SQC         | 138         | 69.9          | 1.762                 |                       |             |                        |
| BM              |             |               |                       |                       |             |                        |
| Absent          | 162         | 87.7          | < 0.001               | < 0.001               | 1           | 1.175–2.502 |
| Present         | 49          | 28.3          |                       |                       | 1           | 1.715       |
| Tumor Cav-1     |             |               |                       |                       |             |                        |
| Low             | 128         | 73.1          | 0.260                 | 0.005                 | 1           | 1.175–2.502 |
| High            | 83          | 71.0          |                       |                       | 1           | 1.715       |

SQC, squamous cell carcinoma

* Cox proportional hazards model for multivariate analysis
Cav-1 expression in BM samples (Fig. 5a). In contrast, SNAIL expression was inversely related to Cav-1 expression in the ADC group (Additional file 3: Figure S2).

In lung SQC cell lines, genetic modulation of Cav-1 was accompanied by SNAIL expression (Fig. 5b, c). Knockdown of Cav-1 by shRNA in H520 cells led to decreased expression of SNAIL at both the protein and mRNA levels. In contrast, overexpression of Cav-1 in H157 cells was related to increased expression of SNAIL. Dual immunofluorescent staining of Cav-1 and SNAIL performed on mock or Cav-1-overexpressing H157 cells supported this finding (Additional file 4: Figure S3). Co-localization of Cav-1 and SNAIL was enhanced in Cav-1-overexpressing cells. Increased invasion ability of Cav-1-overexpressing H157 cells was reduced by a rescue assay using SNAIL-specific siRNA, implying a functional link between Cav-1 and SNAIL (Fig. 5d).

Discussion
The function of Cav-1 in tumors is still under debate. It is unclear whether Cav-1 inhibits or promotes tumor growth and progression. Different types of tumor cells...
are correlated with Cav-1 in various ways [11–24]. In lung cancer, contradictory roles of Cav-1 have been reported [25–37]. Based on an investigation of Cav-1 expression in distinct lung cancer histology, Cav-1 expression was decreased in 95% of SCLC cell lines but maintained in 76% of NSCLC cell lines [25]. In NSCLC, Cav-1 expression was higher in secondary lesions than in primary tumors, as the histology-related tumor aggressiveness increased [36]. Other studies have reported higher Cav-1 expression in pT1 than in pT2–pT4 tumor cells of ADC but lower Cav-1 expression in pT1–pT2 than in pT3–pT4 tumor cells of SQC [35].

**Fig. 4**

**a** Effect of Cav-1 knockdown on the migration of human SQC cell lines. Cav-1 knockdown significantly decreased H1299 and H157 cell invasion, as shown by wound gap distance.

**b** Effect of Cav-1 knockdown on the invasion of human SQC cell lines. Cav-1 knockdown significantly decreased H1299 and H157 cell invasion, as shown by cell counts per field. Bar graphs show the mean ± standard error of the mean (** ***P* < 0.001).

**c** Altered expression of EMT markers and regulators by Cav-1 knockdown in both cell lines. Cav-1 knockdown reduced the expression of EMT markers, including N-cadherin and fibronectin, and reversely increased the expression of E-cadherin, representative epithelial marker. Among the EMT-regulating genes, SNAIL was consistently reduced by Cav-1 knockdown in both cell lines.
Fig. 5. a Representative images of immunohistochemical staining for Cav-1 and SNAIL in BM of the SQC type. Note that the pattern of Cav-1 and SNAIL expression showed a similar direction in the SQC group. The intensity of SNAIL expression increased in proportion to Cav-1 expression in the SQC type (high SNAIL expression: 50% in low intensity of Cav-1 vs. 90% in high intensity of Cav-1, \( P = 0.051 \)).

b Genetic modulation of Cav-1 in lung SQC cell lines (H520 and H157). shRNA knockdown of Cav-1 in H520 cells (Cav-1-sh) and overexpression of Cav-1 in H157 cells (Cav-1-over) led to changes in SNAIL expression in the same direction at both the protein and mRNA levels.

d Rescue assay for possible link between Cav-1 and SNAIL. Increased invasion ability was observed in Cav-1-over H157 cells compared to mock cells. This ability was reduced by SNAIL-specific siRNA for Cav-1-over H157 cells \((P < 0.05, **P < 0.005, ***P < 0.001)\).
In our 211 primary lung cancer cases, higher Cav-1 expression was seen in the SQC (52%) group than in the non-SQC group (33%), supporting a relationship between Cav-1 expression and lung cancer histology. In a comparison of Cav-1 expression between primary lung and secondary BM (53% vs. 84% in paired samples, 52% vs. 78% in whole samples), Cav-1 expression in tumor cells was higher in secondary BM than in primary lung lesions of SQC. This finding suggests that Cav-1 specifically affects BM in lung SQC. Previous investigations have reported the impact of Cav-1 on the tumor microenvironment in some cancers, such as prostate, breast, and pancreas [45–48]. In our study, we found that a low Cav-1 level in stromal cells was related to BM in NSCLC, especially in ADC (data not shown). Although these data should be verified in a larger case series and molecular studies, Cav-1 in the stromal component may be negatively correlated with that in BM of ADC. Recently, Cav-1 expression of fibroblast or macrophage in stromal component has been investigated in primary or secondary lung cancer [49–51].

In the aspect of survival, the poor survival affected by high Cav-1 expression was also observed in other systemic cancer [20–22, 24]. In lung cancer, overexpression of Cav-1 in primary cancer cells was significantly related to poor prognosis in patients with various histotypes [26–31, 34]. On the contrary, some investigations revealed that the survival of patients with NSCLC, especially in ADC, was positively correlated with Cav-1 expression [32, 33, 42]. Our results revealed that Cav-1

---

**Fig. 6** Scheme representing possible role of Cav-1 in BM of SQC lung cancer. High Cav-1 expressing SQC in primary lung cancer is associated increased SNAIL, EMT marker. These cells have more chance to metastasize to the brain compared to low Cav-1 expressed SQC cells.
expression in primary NSCLC is associated with poor survival ($P=0.005, 1.715 \text{ HR}, 1.175–2.502 \text{ 95\% CI}$), in addition to the presence of BM and non-SQC histology. Furthermore, Cav-1 expression in BM was associated with OS in NSCLC patients, although the difference was not significant ($P=0.116$). A similar result was reported that high expression of Cav-1 in BM was correlated with a poor survival rate in lung cancer patients [37]. Although the clinical relevance of Cav-1 expression was not verified according to the histological classification, our study suggested that high Cav-1 expression in tumor cells is definitively related in BM of SQC type and can be a poor independent prognostic factor in NSCLC.

During BM from lung cancer, polarized epithelial cells transform from loose mesenchymal cells, which have enhanced migratory capacity, invasiveness, and production of extracellular matrix, via the EMT [52]. The prominent molecular change is the loss of E-cadherin, a key cell-to-cell adhesion molecule that suppresses tumor metastasis [53]. A number of transcription factors, such as SNAIL, Slug, ZEB1, ZEB2, and TWIST, are well-known EMT inducers, representing increased EMT markers, such as N-cadherin, fibronectin, vimentin, and matrix metalloproteinase. SNAIL strongly represses E-cadherin expression as a potent transcription factor involved in the EMT [54, 55]. SNAIL is highly expressed in NSCLC, and the up-regulation of SNAIL is associated with poor prognosis by promoting tumor progression via the CXCR2 axis [56]. In addition, Cav-1 expression is increased during metastasis via interference with cell adhesion molecules and a loss of polarity in migration [38, 39]. It has also been reported that upregulation of Cav-1 is related to the EMT and influences cancer cell motility [40]. In pancreatic and gastric cancers, the possible association between Cav-1 and SNAIL has been verified, albeit in opposing ways [16, 41]. In the present study, Cav-1 knockdown in lung SQC cell lines resulted in decreased invasion and migration, possibly via a reduction in SNAIL expression. This relationship was supported by IHC data demonstrating that SNAIL expression was increased together with Cav-1 expression in BM samples of the SQC type. These results indicate that Cav-1 regulates cell motility and may affect the EMT via SNAIL, especially in BM of SQC lung cancer (Fig. 6).

**Conclusion**

Cav-1 is believed to play an important role in BM of NSCLC depending on the histotypes. With the finding that Cav-1 expression is higher in BM than primary cancer of the SQC type, we provide pivotal insight into the possible role of Cav-1 on EMT via SNAIL. Clinical findings that high Cav-1 expression is associated with poor clinical outcomes suggest that elucidating Cav-1 function may present a novel and promising therapeutic approach for the treatment of NSCLC. Further studies should be investigated to reveal the connecting mechanism between Cav-1 and the EMT, as well as cancer progression in NSCLC.

**Additional files**

- **Additional file 1: Table S1.** Antibodies used for Western blot analysis.
- **Additional file 2: Figure S1.** Kaplan–Meier analyses of OS for NSCLC patients according to the intensity of Cav-1 expression in BM ($n=105$). NSCLC patients with high Cav-1 expression in BM had a shorter survival period than did those with low Cav-1 expression, although the difference was not significant ($P=0.116$).
- **Additional file 3: Figure S2.** Representative images of immunohistochemical staining for Cav-1 and SNAIL in BM of ADC. In contrast to SQC, the intensity of SNAIL expression was inversely related to Cav-1 intensity in ADC (high SNAIL expression: 94% in low intensity of Cav-1 vs. 67% in high intensity of Cav-1, $P=0.023$).
- **Additional file 4: Figure S3.** Immunofluorescence (IF) of Cav-1 and SNAIL in Cav-1-overexpressing H157 cells. IF was performed as described below: Mock and Cav-1-over H157 cells were grown on Lab-Tek II chamber slides (Thermo Fisher Scientific). Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) and permeabilized in 0.1% Tween-20 for 20 min each, and then blocked in 2% bovine serum albumin for 30 min. The cells were co-incubated overnight at 4 °C in mouse anti-Cav-1 (1:50, BD Biosciences, Franklin Lakes, NJ, USA, Catalog# BD 610407) and rabbit anti-SNAIL (1:50, Santa Cruz Biotechnology Inc., Dallas, TX, USA, Catalog# sc-28199) primary antibodies. After washing in PBS, the cells were co-incubated in goat anti-mouse IgG (1:100, Life Technologies, Catalog# A-11001) and goat anti-rabbit IgG (1:100, Life Technologies Catalog# A1011) secondary antibodies for 1 h at room temperature. Cells were then incubated with DAPI (1:1000) for 20 min followed by washing in PBS. The chamber slides were mounted with antifade mounting medium and imaged in a confocal microscope (Olympus FV1000). The intensity of Cav-1 and SNAIL were determined by using ImageJ software. Increased expression of both Cav-1 and SNAIL was observed in Cav-1-overexpressing H157 cells compared to mock cells ($**P<0.005$).

**Abbreviations**

- ADC: adenocarcinoma
- BM: brain metastasis
- Cav-1: caveolin-1
- DMEM: Dulbecco’s Modified Eagle’s Medium
- EMT: epithelial-mesenchymal transition
- FBS: fetal bovine serum
- NSCLC: non-small cell lung cancer
- OS: overall survival
- SQC: small cell lung cancer
- siRNA: small interfering RNA
- SQC: squamous cell carcinoma

**Acknowledgements**

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/aX1pSz.

**Authors’ contributions**

KHL and KSM designed this study. SJO, OK, EJA, HK, MRA and HSK carried out the experiment. YJK, JHK, KHL and MRA and HSK collected clinical data. JHL and KHL carried out pathological examination. KHL and KSM carried out the statistical analysis. SJ, KKK, HSK, HK and JHL assisted with the manuscript preparation and data analysis. All authors read and approved the final manuscript.

**Funding**

This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Minst (2016R1A2B1014597 for KHL, 2016R1C1B2007494 for KSM) and Chonnam National University Hospital Biomedical Research Institute (HCR17902-21 for KSM). This work was also supported by the National Research
References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
2. Travis WD, Brambilla E, Burke AP, Nicholson AJ. Introduction to The 2015 World Health Organization Classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240–2.
3. Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type. Cancer. 2014;120(8):2883–92.
4. Knights EM Jr. Metastatic tumors of the brain and their relation to primary and secondary pulmonary cancer. Cancer. 1954;7(2):259–65.
5. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain cancer versus small cell lung cancer. Cancer Res. 2004;64(12):4277–85.
6. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, et al. Cancer Cell Int. 2019;19:171.
7. Cohen AH, Hinasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev. 2004;84(4):1341–79.
8. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing “preassembled signaling complexes” at the plasma membrane. J Biol Chem. 1998;273(10):5419–22.
9. Sotgia F, Williams TM, Schubert W, Medina F, Minetti C, Pestell RG, Lisanti MP. Caveolin-1 deficiency (−/−) conveys premyelination alterations in mammalian epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol. 2006;168(1):292–309.
10. Frank PG, Cheung MW, Pavlidis S, Llaverias G, Park DS, Lisanti MP. Caveolin-1 and regulation of cellular cholesterol homeostasis. Am J Physiol Heart Circ Physiol. 2006;291(2):H677–86.
11. Fong A, Garcia E, Gwynn L, Lisanti MP, Fazzari MJ, Li M. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am J Clin Pathol. 2003;120(1):93–100.
12. Hatanaka M, Maeda T, Ikemoto T, Mori H, Seya T, Shimizu A. Expression of caveolin-1 in human T cell leukemia cell lines. Biochem Biophys Res Com- mun. 1998;253(2):382–7.
13. Taher SA, Yang G, Ebara S, Timme TL, Sato T, Li L, et al. Secreted caveolin-1 stimulates cell survival/division growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001;61(10):3882–5.
14. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer. 2002;94(4):929–35.
15. Goetz K, Lapie P, Wiseman SM, Nabi IR. Caveolin-1 is tumor progression: the good, the bad and the ugly. Cancer Meta Rev. 2008;27(4):715–35.
16. Salem AF, Bonuccelli G, Bevilacqua G, Arafat H, Pestell RG, Sotgia F, et al. Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition. Cell Cycle. 2011;10(21):3692–700.
17. Rendler FC, Reymond MA, Boon C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 2000;60(20):5870–8.
18. Wiechen K, Diatchenko L, Agoulinik A, Scharff KM, Schober H, Arti K, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001;159(5):1635–43.
19. Cokakli M, Erdal E, Nart D, Yilmaz F, Sagol O, Kilic M, et al. Differential expression of caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer. 2009;9:65.
20. Senetta R, Trevisan E, Ruda M, Eolin L, Molinaro L, Lefranc F, et al. Caveolin-1 expression independently predicts shorter survival in oesophagealcarcinomas. J Neurouropath Exp Neurol. 2009;68(4):425–31.
21. Senetta R, Miracco C, LanzaFame S, Chiusa L, Calabria R, Giaia A, Stella G, Cassoni P. Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes. Neuro-oncology. 2011;13(2):176–83.
22. Liu L, Xu HK, Wang WQ, Wu CT, Chen T, Qin Y, et al. Cavatin 1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene. 2014;33(21):2729–6.
23. Yu H, Shen H, Zhang Y, Zhong F, Liu Y, Qin L, Yang P. CAV1 promotes HCC cell progression and metastasis through Wnt/beta-catenin pathway. PLoS ONE. 2014;9(9):e106451.
24. Mao X, Cheng SY, Tse EY, Ko FC, Tse Y, Ko FC, et al. Mechanisms through which hypoxia-induced caveolin-1 drives tumorigenesis and metastasis in hepatocellular carcinoma. Cancer Res. 2016;76(24):7242–53.
25. Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD, et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 2004;64(12):4277–85.
26. Moon KC, Lee GY, Yoo SH, Jeon YK, Chung JH, Han J, et al. Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Res. 2005;25(6c):4631–7.
27. Zhan R, Shen XY, Qian Q, Wang Q, Zhu JP, Zhang Y, et al. Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas. Oncol Rep. 2012;27(4):1072–8.
28. Duregon E, Senetta R, Bertero L, Bussolati B, Annaratone L, Pottaro A, et al. Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. Tumour Biol. 2017;39(2):10142813.7694311.
29. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008;59(1):105–10.
30. Brodie SA, Lombardo C, Li G, Kowalski J, Gandhi K, You S, et al. Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC. PLoS ONE. 2014;9(9):e107124.
31. Chen HL, Fan LF, Gao J, Ouyang JP, Zhang YX. Differential expression and function of the caveolin-1 gene in non-small cell lung cancer. Oncol Rep. 2011;25(2):359–66.

32. Tian ZQ, Li ZH, Wen SW, Zhang YF, Li Y, Cheng JG, et al. Identification of Commonly Dysregulated Genes in Non-small-cell Lung Cancer by Integrated Analysis of Microarray Data and qRT-PCR Validation. Lung Cancer. 2015;93(4):583–92.

33. Joo JC, Hwang JH, Jo E, Kim YR, Kim DJ, Lee KB, et al. Cordycepin induces apoptosis by caveolin-1-mediated JNK regulation of Foxo3a in human lung adenocarcinoma. Oncotarget. 2017;8(7):12211–24.

34. Wang Y, Liu B, Xu Y, Zhang J, Xia Q, Yu B, et al. Correlation of caveolin-1 expression with clinicopathologic features and prognosis in patients with lung adenocarcinoma. Zhonghua Bing Li Xue Za Zhi. 2014;43(4):251–5.

35. Kato T, Miyamoto M, Kato K, Cho Y, Itoh T, Morikawa T, et al. Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. Cancer Lett. 2004;214(1):121–8.

36. Cassoni P, Daniele L, Maldi E, Righi L, Tavaglione V, Novello S, et al. Caveolin-1 expression in lung carcinoma varies according to tumor histotype and is acquired de novo in brain metastases. Histopathology. 2009;55(1):20–7.

37. Duregon E, Senetta R, Pittaro A, Verdun di Cantogno L, Stella G, De Blasi F, et al. CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype. Oncotarget. 2015;6(30):29626–36.

38. Beardsley A, Fang K, Mertz H, Castranova V, Friend S, Liu J. Loss of caveolin-1 polarity impedes endothelial cell polarization and directional movement. J Biol Chem. 2005;280(5):3541–7.

39. Grande-Garcia A, Echam J, de Rooij J, Alderson NB, Waterman-Storer CM, Valdivielso JM, et al. Caveolin-1 regulates cell polarization and directional migration through Src kinase and Rho GTPases. J Cell Biol. 2007;177(4):683–94.

40. Bailey KM, Liu J. Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase. J Biol Chem. 2007;282(20):13714–24.

41. Kannan A, Krishnan A, Ali M, Subramaniam S, Halagovder D, Sivasithamparam ND. Caveolin-1 promotes gastric cancer progression by up-regulating epithelial to mesenchymal transition by crosstalk of signalling mechanisms under hypoxic condition. Eur J Cancer. 2014;50(1):204–15.

42. Fan CC, Cheng WC, HuangYC, Sher YP, Liu NJ, Chien YC, et al. EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma. Sci Rep. 2017;7(1):14617.

43. Lee KH, Ahn EJ, Oh SJ, Kim O, Joo YE, Bae JA, et al. KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers. Oncotarget. 2015;6(5):3240–53.

44. Choi RH, Kim HS, Park MS, Kim JT, Kim JH, Cho KA, et al. Regulation of caveolin-1 expression determines early brain edema after experimental focal cerebral ischemia. Stroke. 2016;47(5):1336–43.

45. Ayala G, Morello M, Frolow A, You S, Li R, Rosati F, et al. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol. 2013;229(1):77–87.

46. Martins D, Beca FE, Sousa B, Baltazar F, Paredes J, Schmitt F. Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: key events in the progression from an in situ to an invasive breast carcinoma. Cell Cycle. 2013;12(16):2684–90.